Review
Ledipasvir/Sofosbuvir (Harvoni): For the Treatment of Chronic Hepatitis C Virus (CHC) G1 Infection in Adults [Internet]
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jul.
- PMID: 27227210
- Bookshelf ID: NBK362643
Item in Clipboard
Review
Ledipasvir/Sofosbuvir (Harvoni): For the Treatment of Chronic Hepatitis C Virus (CHC) G1 Infection in Adults [Internet]
Excerpt
The objective of this report was to perform a systematic review of the beneficial and harmful effects of ledipasvir plus sofosbuvir (LDV/SOF) for the treatment of chronic hepatitis C virus (HCV) G1 infection in adults.
Copyright © CADTH 2015.
Sections
-
Clinical Review Report
- ABBREVIATIONS
- EXECUTIVE SUMMARY
- 1. INTRODUCTION
- 2. OBJECTIVE AND METHODS
- 3. RESULTS
- 4. DISCUSSION
- 5. CONCLUSIONS
- APPENDIX 1 PATIENT INPUT SUMMARY
- APPENDIX 2 LITERATURE SEARCH STRATEGY
- APPENDIX 3 EXCLUDED STUDIES
- APPENDIX 4 DETAILED OUTCOME DATA
- APPENDIX 5 VALIDITY OF OUTCOME MEASURES
- APPENDIX 6 APPRAISAL OF MANUFACTURER-SUBMITTED INDIRECT COMPARISON
- REFERENCES
-
Pharmacoeconomic Review Report
- ABBREVIATIONS
- EXECUTIVE SUMMARY
- 1. SUMMARY OF THE MANUFACTURER’S PHARMACOECONOMIC SUBMISSION
- 2. MANUFACTURER’S BASE CASE
- 3. SUMMARY OF MANUFACTURER’S SENSITIVITY ANALYSES
- 4. LIMITATIONS OF MANUFACTURER’S SUBMISSION
- 5. CADTH COMMON DRUG REVIEW ANALYSES
- 6. ISSUES FOR CONSIDERATION
- 7. PATIENT INPUT
- 8. CONCLUSIONS
- APPENDIX 1 COST COMPARISON
- APPENDIX 2 SUMMARY OF KEY OUTCOMES
- APPENDIX 2 ADDITIONAL INFORMATION
- APPENDIX 3 REVIEWER WORKSHEETS
- REFERENCES
- CDEC Final Recommendation
Publication types
LinkOut - more resources
Full Text Sources
